Lung cancer is the leading cause of cancer-related death in the United States . Recent epidemiological studies have shown an increasing incidence of lung cancer among young women than in young men for the first time in the history of the disease . In recent years, extensive research in the field has led to the establishment of immunotherapy and personalized targeted therapy as frontline treatment strategies for advanced non-small-cell lung cancer . Next-generation tyrosine kinase inhibitors and immune checkpoint inhibitors are the standard of care in various types of advanced lung cancers based on the detection of biomarkers such as EGFR, ALK, ROS1, MET skip 14 mutations, NTRK, RET and PD-L1, and have prolonged lung cancer survival from months, to in some instances, years .
To view the full article, please register now for access